Logo

ADL/Metabolomic Technologies' PolypDx Urine-Based Diagnostic Test

Jun 29, 2016

Atlantic Diagnostic Laboratories has launched Metabolomic Technologies' PolypDx, a non-invasive urine-based test for detection of adenomatous polyps, the precursor to colorectal cancer. PolypDx only requires a small urine sample for analysis. In a Canadian clinical trial the test demonstrated significantly higher sensitivity than a current fecal-based screening test to detect adenomatous polyps, the company said.

PolypDX is the flagship product of Metabolomic Technologies, a privately held Canadian company that has given ADL exclusive licensing and distribution rights to bring the test to the US market.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.